Physician profile
Julia Freeze
NPI 1851739429
$1,661.59
in general payments reported to CMS, 2019-2025
22 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $84.00 · 2021: $106 · 2022: $64.95 · 2023: $328 · 2024: $414 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.22 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $354.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $207.28 | 2021-2025 | |
| Pfizer INC. | $145.58 | 2019-2025 | |
| Lilly USA, LLC | $144.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.06 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $110.43 | 2024-2025 | Farxiga, Breztri |
| Amgen INC. | $99.46 | 2019-2023 | Prolia, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $90.76 | 2019-2024 | Trintellix |
| Glaxosmithkline, LLC. | $49.06 | 2021-2025 | Penmenvy, Bexsero |
| Novartis Pharmaceuticals Corporation | $46.80 | 2019 | |
| Abbott Laboratories | $45.36 | 2023-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $41.90 | 2023-2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $38.34 | 2023-2025 | Inspire |
| Viatris Specialty LLC | $25.78 | 2025 | Yupelri |
| Amarin Pharma, INC. | $21.27 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $18.95 | 2024 | Rexulti |
| Dexcom, INC. | $17.52 | 2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $16.50 | 2020 | |
| Astellas Pharma US INC | $16.50 | 2023 | Veozah |
| Arbor Pharmaceuticals, INC. | $16.20 | 2020 | |
| Shire North American Group INC | $14.96 | 2019 | |
| Merck Sharp & Dohme LLC | $14.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Freeze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.